The following tumor biomarkers may be used to select treatment for the cancer types listed below. Speak with your doctor about other tests and treatments, which may be available.

	Cancer							Treatment/s
	Breast	Colorectal	Endometrial	Melanoma	Ovarian	Pancreatic
BRAFV600E		X		X				Braftovi (encorafenib) Braftovi in combination with Mektovi (binimetinib) Cotellic (cobimetinib) Zelboraf (vemurafenib)
,					X		X	Lynparza () Rubraca () Zejula® ()
Epidermal growth factor receptor (EGFR) mutation testing		X						Erbitux (cetuximab) Vectibix (panitumumab)
Estrogen/Progesterone receptor (ER/PR) expression	X		X					Aromatase inhibitors (AIs) Tamoxifen Raloxifene
expression	X	X	X					Herceptin (trastuzumab) Perjeta (pertuzumab) Tukysa (tucatinib) Kadcyla (ado-trastuzumab emtansine) Enhertu(fam-trastuzumab-deruxtecan-nxki or T-DXd)
Deficiency ()					X			Lynparza () Zejula® ()
Response (HRR) pathway mutations (, , , , , CDK12, , FANCL, , RAD51B, , , RAD54)							X	Lynparza ()
KRAS mutation		X						Erbitux (cetuximab) Vectibix (panitumumab)
MSI-H () or dMMR/MMR-D (Mismatch Repair Deficient)	X	X	X	X	X	X	X	Keytruda (pembrolizumab)
MSI-H () or dMMR/MMR-D (Mismatch Repair Deficient)		X						Opdivo (nivolumab) Yervoy (ipilimumab)
dMMR/MMR-D (Mismatch Repair Deficient)			X					Jemperli (dostarlimab)
NTRK fusion	X	X	X	X	X	X	X	Vitrakvi (larotrectinib)
PDL1 expression	X							Tecentriq (atezolizumab)
PIK3CA	X							Piqray (alpelisib),
(TMB)	X	X	X	X	X	X	X	Keytruda (pembrolizumab)

Last updated August 10, 2022